BAVA Bavarian Nordic A/S

36.42USD248.20 DKK · CPH+2.14%Mkt Cap: 2.72B USDP/E: 22.34

Bavarian Nordic A/S develops, manufactures, and supplies life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human u…

Institutional holders10 on file

Key Statistics

Company
Market Cap2.72B USD
Enterprise Value2.30B USD
Revenue (TTM)931.53M USD
Gross Profit447.36M USD
Net Income (TTM)201.82M USD
Revenue/Share11.68 USD
Last Price36.42 USD
Fiscal Year EndDec 2025
MR QuarterSep 2026
Employees1.9K
CountryDK
SectorHealthcare
IndustryBiotechnology
ISINDK0015998017
Valuation
P/E (Trailing)22.34
P/E (Forward)20.43
PEG1.87
EV/EBITDA8.29
EV/Revenue2.47
P/S2.92
P/B1.38
EPS (TTM)1.63 USD
EPS (Forward)1.78 USD
52W Range
25.1490% of range37.71
52W High37.71 USD
52W Low25.14 USD
Profitability
Gross Margin48.83%
Oper. Margin19.67%
EBITDA Margin29.74%
Profit Margin22.03%
ROE10.69%
ROA9.20%
ROIC14.25%
ROCE13.51%
Growth
Revenue Growth0.60%
Earnings Growth-60.60%
Cash Flow & Leverage
Operating CF399.41M USD
CapEx (TTM)199.46M USD
FCF Margin4.92%
FCF Yield1.69%
Net Debt-419.89M USD
Net Debt/EBITDA-1.52
Net Debt/FCF-9.16
Balance Sheet
Debt/Equity0.01
Current Ratio6.56
Quick Ratio4.13
Book Value/Sh26.36 USD
Cash/Share5.87 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)43.66 USD
Upside (mean)+19.9%
Target Range41.09 USD – 45.49 USD
41.09+19.9% to mean45.49
# Analysts4
Ownership
Shares Out.74.60M
Float74.56M
Insiders0.01%
Institutions35.43%
Technical
SMA 5033.91 (+7.4%)
SMA 20029.37 (+24.0%)
Beta1.02
S&P 52W Chg12.00%
Avg Vol (30d)203.95K
Avg Vol (10d)173.62K
Technical Indicators
RSI (14)59.1
MACD2.2823
MACD Signal3.2944
MACD Hist.-1.0121
BB Upper37.60 USD
BB Middle36.01 USD
BB Lower34.41 USD
BB Width8.84%
ATR (14)0.9497 USD
Vol Ratio (20d)2.00x

About Bavarian Nordic (CPH: BAVA)

›

Bavarian Nordic (CPH: BAVA) is listed on Nasdaq Copenhagen, where its shares trade in DKK. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 1,923 employees.

The shares were at 248.20 DKK on 19 November 2026, up 30.7% over 52 weeks. Its 52-week range is 171.30 DKK to 257.00 DKK: the price is 3.4% below the high and 44.9% above the low.

At a market capitalisation of 18.52B DKK, it trades at 22.3 times trailing earnings and 20.4 times forward earnings. The median trailing P/E of its 13 largest Biotechnology peers is 33.5, a discount of 33% for BAVA.

Bavarian Nordic reports return on equity of 10.7%, an operating margin of 19.7% and revenue up 0.6% year over year.

It holds more cash than debt, a net cash position of 2.86B DKK. Its Piotroski F-score is 8 out of 9, a strong reading of its financial health. 4 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 297.50 DKK is 19.9% above the current price.